[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icd-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icd-patients":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100590300",false,"NCT06965621","18F-mFBG Imaging for Myocardial Sympathetic Innervation","An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators","Inclusion Criteria:\n\n* Stable heart failure from ischemic cardiomyopathy, LVEF \\\u003C or = 35%, ICD implantation for at least 12 months\n\nExclusion Criteria:\n\n* Unstable coronary artery disease, no ICD implantation","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation. The study will examine a group of stable patients with heart failure (HF) from ischemic cardiomyopathy. All subjects will have left ventricular ejection fraction (LVEF) ≤35% and implantable cardioverter-defibrillators (ICD). The primary objectives of the study will be to:\n\n* document the degree to which 18F-mFBG uptake in the heart is reduced (compared to historical controls)\n* characterize the distribution of regional abnormalities in relation to findings on rest\u002Fstress positron-emission tomography (PET) myocardial perfusion imaging (MPI)\n* determine if there are global and\u002For regional differences in myocardial sympathetic innervation between subjects who have and have not experienced an appropriate ICD activation within the previous 12 months Effectiveness of 18F-mFBG will be judged in relation to historical experience with other nuclear imaging agents for cardiac sympathetic innervation imaging such as a 123I-meta-iodobenzylguanidine (mIBG) and 11C-hydroxyephedrine (HED).\n\nSafety data will be collected to identify adverse events \\[AEs\\] and serious adverse events \\[SAEs\\] and characterize the safety profile of 18F-mFBG.",[25,26,27],"Heart Failure","Ischemic Cardiomyopathy","ICD Patients",[29,30,31],"Myocardial sympathetic innervation","PET myocardial imaging","18F-mFBG","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2025-11-05",{"date":40,"type":19},"2026-12-30",{"name":42,"class":43},"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","INDUSTRY",""]